Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Monoclonal antibodies

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    554 result(s) found for: Monoclonal antibodies. Displaying page 1 of 28.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-005051-37 Sponsor Protocol Number: NL78705.018.21 Start Date*: 2021-12-06
    Sponsor Name:Amsterdam University Medical Centre
    Full Title: TURN-COVID Biobank: The Dutch cohort study for the evaluation of the use of neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002096-34 Sponsor Protocol Number: AER-2012 Start Date*: 2012-10-29
    Sponsor Name:Crucell Holland B.V.
    Full Title: Research towards presence of Antibodies against European Bat Lyssavirus (EBLV) after immunization with Rabipur®
    Medical condition: healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10069589 Rabies immunization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005189-31 Sponsor Protocol Number: 181114 Start Date*: 2014-12-16
    Sponsor Name:Dept Hematology SLB Vejle [...]
    1. Dept Hematology SLB Vejle
    2. Dept Hematology SLB Vejle
    Full Title: “Monoclonal antibodies for treatment of multiple myeloma. Present status and aspects of effector mechanisms with emphasis on the CD38 antibody daratumumab ”.
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10028567 Myeloma, malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004243-21 Sponsor Protocol Number: M200-1205 Start Date*: 2005-03-15
    Sponsor Name:PDL BioPharma, Inc.
    Full Title: Phase 2 Open-Label Study of Volociximab (M200) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Cancer Not Previously Treated with Chemotherapy
    Medical condition: metastatic pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002927-39 Sponsor Protocol Number: BOOST_TX/RESCUE_TX Start Date*: 2021-06-13
    Sponsor Name:Medical University of Vienna
    Full Title: Preventive strategies against SARS-CoV-2 in kidney transplant recipients: Intervention A – vaccination: Single blinded randomized controlled trial on BNT162b2 or mRNA-1273 (mRNA) vs Ad26COVS1 or C...
    Medical condition: Intervention A - vaccination Patients following kidney transplant recipients who do not have an adequate immune response against SARS-CoV-2 following two doses of an mRNA vaccine Substudy A: kidne...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003314-39 Sponsor Protocol Number: 78934804CRD2001 Start Date*: 2023-02-21
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Gusel...
    Medical condition: Moderately to Severely Active Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) AT (Ongoing) PT (Trial now transitioned) BG (Trial now transitioned) IE (Completed) NO (Trial now transitioned) SI (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000618-39 Sponsor Protocol Number: Sym004-13 Start Date*: 2018-10-23
    Sponsor Name:Symphogen A/S
    Full Title: A Phase 2, Randomized, Open-Label, Multicenter, Three-Arm Trial of Sym004 versus each of its Component Monoclonal Antibodies, Futuximab and Modotuximab, in Patients with Chemotherapy-Refractory Met...
    Medical condition: Metastatic Colorectal Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004994-94 Sponsor Protocol Number: 3415A-002 Start Date*: 2011-12-21
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. difficile toxin B), and MK-...
    Medical condition: Recurrence of Clostridium difficile infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed) CZ (Completed) FI (Completed) PL (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000721-53 Sponsor Protocol Number: ITT-PMSExt Start Date*: 2012-12-07
    Sponsor Name:Dept of Neurology, Umeå University Hospital, Umeå, Sweden
    Full Title: ITT-PMS Extension An extension study of intrathecal therapy with monoclonal antibodies in progressive multiple sclerosis
    Medical condition: Secondary progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000015-24 Sponsor Protocol Number: 07MI05 Start Date*: 2015-04-10
    Sponsor Name:Great Ormond Street Hospital
    Full Title: 90-Yttrium-labelled anti-CD66 monoclonal antibody as part of a reduced intensity conditioning regimen prior to allogeneic haematopoietic stem cell transplantation: an open label, dose escalating ph...
    Medical condition: High risk relapsed or refractory leukaemia in childhood
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-005528-39 Sponsor Protocol Number: 78934804UCO2001 Start Date*: 2023-02-16
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Gusel...
    Medical condition: Moderately to Severely Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) HU (Ongoing) CZ (Trial now transitioned) NL (Trial now transitioned) SK (Trial now transitioned) AT (Trial now transitioned) BG (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) PT (Trial now transitioned) SI (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004535-84 Sponsor Protocol Number: R10933-10987-COV-2114 Start Date*: 2022-11-21
    Sponsor Name:Regeneron Pharmaceuticals Inc.
    Full Title: A Phase 1b, Open-Label, Single Dose Study Assessing the Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) f...
    Medical condition: Coronavirus disease 2019
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004590-90 Sponsor Protocol Number: 3415A-001 Start Date*: 2012-02-17
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium ...
    Medical condition: recurrence of Clostridium difficile infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) CZ (Completed) BE (Completed) DK (Completed) PT (Completed) AT (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004486-26 Sponsor Protocol Number: IGG-SN-MAB2 Start Date*: 2008-10-07
    Sponsor Name:ISTITUTO GIANNINA GASLINI
    Full Title: Efficacy of monoclonal anti CD 20 antibodies in steroid and cyclosporin dependent nephrotic syndrome in children
    Medical condition: Nephrotic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029164 Nephrotic syndrome LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003503-34 Sponsor Protocol Number: Uni-Koeln-4288 Start Date*: 2020-12-01
    Sponsor Name:University of Cologne
    Full Title: A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals
    Medical condition: SARS-CoV-2 infection (only mild to moderate disease)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004448-27 Sponsor Protocol Number: Uni-Koeln-4370 Start Date*: 2020-12-04
    Sponsor Name:University of Cologne
    Full Title: A Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals
    Medical condition: SARS-CoV-2 infection (only mild to moderate disease)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004590-30 Sponsor Protocol Number: R10933-10987-COV-2121 Start Date*: 2022-09-23
    Sponsor Name:Regeneron Pharmaceuticals Inc.
    Full Title: A Phase 2a, Open-Label Study Assessing Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Single-Dose Subcutaneous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab and Imdevim...
    Medical condition: Coronavirus disease 2019
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-002286-32 Sponsor Protocol Number: 6125 Start Date*: 2009-08-10
    Sponsor Name:Queen Mary Medical University of London
    Full Title: Phase I/II Study combining humanised anti-CD20 (veltuzumab), anti-CD22 (epratuzumab) and both monoclonal antibodies with chemotherapy in adults with recurrent B precursor acute lymphoblastic leukae...
    Medical condition: This is a phase I/ II trial to determine the efficacy of intravenous veltuzumab and epratuzmab either individually or together in combination with chemotherapy in patients with recurrent acute lymp...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003890 B precursor type acute leukaemia LLT
    9.1 10003917 B-cell type acute leukaemia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003993-24 Sponsor Protocol Number: CA186006 Start Date*: 2008-05-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or Stage IV Melanoma. Revised Protocol 0...
    Medical condition: MELANOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025670 Malignant melanoma stage III LLT
    9.1 10025671 Malignant melanoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003246-93 Sponsor Protocol Number: D3461C00008 Start Date*: 2016-12-06
    Sponsor Name:Astrazeneca AB
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in ...
    Medical condition: Systemic Lupus Erythematosus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 02:14:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA